Abiraterone Acetate Tablet
Product Images NDC 51407-503

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Abiraterone Acetate (NDC 51407-503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-503-12ol (Abiraterone 125mg)

This text provides important information about Abiraterone Acetate tablets, including dosage instructions, warnings for pregnant women, storage recommendations, and the importance of swallowing the tablets whole. It also directs pharmacists to dispense patient information with each prescription. For further details, the package insert should be consulted. The tablets are marketed by GSMS, Incorporated in Camarillo, California.*

FDA Label Image

Image Description (Yonsa 1)

FDA Label Image

Image Description (Yonsa 2)

The text is an evaluation of Abiraterone Acetate versus Placebo in a study related to time to death in months. The numbers provided show the comparison between the two treatment groups.*

FDA Label Image

Image Description (Yonsa 3)

This text appears to be a table showing the number of subjects without death over time for two groups - Placebo and Abiraterone Acetate. The numbers under the "w2" column represent the weeks from randomization. The data seems to be related to a clinical study or trial, possibly on the efficacy of Abiraterone Acetate.*

FDA Label Image

Image Description (Yonsa 4)

The text provides information about a study comparing Abiraterone Acetate to a placebo in a treatment group. The data shows the number of subjects in each group at different time points from randomization. The study appears to have included a total of 546 subjects receiving Abiraterone Acetate and 542 receiving a placebo. The numbers at various time points suggest the follow-up of subjects over multiple months post-randomization.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.